In a stinging setback for Roche (RHHBY.PK), an advisory panel recommended the FDA revoke...

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

In a stinging setback for Roche (RHHBY.PK), an advisory panel recommended the FDA revoke approval for Avastin as a treatment for breast cancer, saying the drug wasn't helping patients. Avastin is currently the world's best-selling cancer drug, and its revocation could cost Roche $1B in annual revenue.